Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 106, Issue 2, 2012, Pages 84-89

  Namuwenge, P M ^a,b   Mukonzo, J K ^c   Kiwanuka, N ^a   Wanyenze, R ^a   Byaruhanga, R ^b   Bissell, K ^d   Zachariah, R ^e  

^a MAKERERE UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Uganda)

^b AIDS Information Centre headquarters   (Uganda)

^c MAKERERE UNIVERSITY   (Uganda)

^d INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^e MÉDECINS SANS FRONTIÈRES   (Switzerland)

Author keywords

IPT; Loss to follow up; NGO; Uganda; VCT

Indexed keywords

ISONIAZID; PYRIDOXINE; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ADULT; AFTERCARE; ARTICLE; DRUG SELF ADMINISTRATION; FEMALE; FEVER; HEMOPTYSIS; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISONIAZID PREVENTIVE TREATMENT; LOSS TO FOLLOW UP; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NIGHT SWEAT; PATIENT COMPLIANCE; PATIENT COUNSELING; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; PREVENTIVE MEDICINE; RISK FACTOR; SPUTUM CULTURE; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; UGANDA; WEIGHT REDUCTION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; COUNSELING; FEMALE; HUMANS; ISONIAZID; LOST TO FOLLOW-UP; MALE; RETROSPECTIVE STUDIES; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS; UGANDA;

EID: 84855552270     PISSN: 00359203     EISSN: 18783503     Source Type: Journal    
DOI: 10.1016/j.trstmh.2011.10.015     Document Type: Article

References (27)

1. WHO. Global tuberculosis control 2009. Epidemiology, strategy, financing. Geneva: World Health Organization; 2009.
2. Sonnenberg P., Glynn J.R., Fielding K., Murray J., Godfrey-Faussett P., Shearer S. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005, 191:150-158.
3. De Cock K.M., Chaisson R.E. Will DOTS do it?. A reappraisal of tuberculosis control in countries with high rates of HIV infection. Int J Tuberc Lung Dis 1999, 3:457-465.
4. Ansari N.A., Kombe A.H., Kenyon T.A., Hone N.M., Tappero J.W., Nyirenda S.T., et al. Pathology and causes of death in a group of 128 predominantly HIV positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002, 6:55-63.
5. Corbett E.L., Marston B., Churchyard G.J., De Cock K.M. Tuberculosis in sub-Saharan Africa: opportunities, challenges, and change in the era of antiretroviral treatment. Lancet 2006, 367:926-937.
6. Ait-Khaled N., Alarcon E., Bissell K., Boillot F., Caminero J.A., Chiang C.Y., et al. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis 2009, 13:927-935.
7. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews 2010. Art. No.: CD000171 doi:10.1002/14651858.CD000171.pub3.
8. WHO; UNAIDS. Policy statement on preventive therapy against tuberculosis in people living with HIV. WHO/TB/98.255 UNAIDS/98.34. Geneva: World Health Organization; 1998.
9. WHO. Guidelines for intensified Tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. 2010.
10. Smart T. IPT for TB in people with HIV: barriers to national implementation. 2008; 39-46. http://www.aidsmap.com/files/file1002936.pdf.
11. Uganda Ministry of Health. National policy guidelines for TB/HIV collaborative activities in Uganda. Kampala: Ministry of Health; 2006.
12. Johnson J.L., Okwera A., Hom D.L., Mayanja H., Mutuluuza C., Kityo P., et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001, 15:2137-2147.
13. Lugada E.S., Watera C., Nakiyingi J., Elliott A., Brink A., Nanyunja M., et al. Operational assessment of isoniazid prophylaxis in a community AIDS service organisation in Uganda. Int J Tuberc Lung Dis 2002, 6:326-331.
14. Whalen C.C., Johnson J.L., Okwera A., Hom D.L., Huebner R., Mugyenyi P., et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodefeciency virus. N Engl J Med 1997, 337:801-808.
15. Uganda Ministry of Health. Uganda National Policy Guidelines for HIV counseling and testing. Kampala: Ministry of Health; 2005.
16. Chijioke A.N., Osaro E., Oseikhuemen A.E. Adherence to antiretroviral therapy among HIV-infected subjects in a resource - limited setting in the Niger Delta of Nigeria. Afr J Health Sci 2006, 13:13-17.
17. Uganda Ministry of Gender, Labour and Social Development. Labour markets information status report for Uganda. Kampala: Ministry of Gender, Labour and Social Development; 2006.
18. Li J., Munsiff S.S., Tarantino T., Dorsinville M. Adherence to treatment of latent tuberculosis infection in a clinical population in New York City. Int J Inf Dis 2010, 4:e292-e297.
19. Cauldbeck M.B., O'Connor C., O'Connor M.B., Saunders J.A., Rao B., Mallesh V.G., et al. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Res Ther 2009, 6. 10.1186/1742-6405-6-7.
20. Frank I. Once daily HAART: toward a new treatment paradigm. J Acquir Immune Defic Syndr 2002, 31(Suppl 1). S10-5.S24-5.
21. Murri R., Ammassari A., De Luca A., Cingolani A., Marconi P., Wu A.W., et al. Self-reported nonadherence with antiretroviral drugs predicts persistent condition. HIV Clin Trials 2001, 2:323-329.
22. Wandwalo E.R., Mørkve O. Knowledge of disease and treatment among tuberculosis patients in Mwanza, Tanzania. Int J Tuberc Lung Dis 2000, 4:1041-1046.
23. Joung I.M., van der Meer J.B., Mackenbach J.P. Marital status and health care utilization. Int J Epidemiol 1995, 24:569-575.
24. Simoni J.M., Frick P.A., Lockhart D. Mediators of social support and antiretroviral adherence among an indigent population in New York City. AIDS Patient Care STDs 2002, 16:431-439.
25. Zea M.C., Reisen C.A., Poppen P.J., Bianchi F.T., Echeverry J.J. Disclosure of HIV status and psychological well-being among Latino gay and bisexual men. AIDS Behav 2005, 9:15-26.
26. Skogmar S., Shakely D., Lans M., Danell J., Andersson R., Tshandu N., et al. Effect of antiretroviral treatment and counselling on disclosure of HIV-serostatus in Johannesburg, South Africa. AIDS Care 2006, 18:725-730.
27. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P., et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370:1453-1457.